<div id="readability-page-1">CONMED (NYSE:CNMD - Get Free Report) was downgraded by analysts at Wall Street Zen from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a note issued to investors on Saturday.<ul><li>Med-tech stock Conmed dips ahead of big Q4 report...opportunity?</li></ul>A number of other research firms have also recently issued reports on CNMD. Zacks Research upgraded shares of CONMED from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, February 3rd. Wells Fargo &amp; Company cut their target price on shares of CONMED from $42.00 to $39.00 and set an &#34;equal weight&#34; rating for the company in a research note on Friday. Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of CONMED in a research note on Wednesday, January 21st. Piper Sandler cut shares of CONMED from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and cut their target price for the company from $55.00 to $39.00 in a research note on Tuesday, March 17th. Finally, Needham &amp; Company LLC reiterated a &#34;hold&#34; rating on shares of CONMED in a research note on Thursday, January 29th. Six research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, CONMED presently has a consensus rating of &#34;Reduce&#34; and a consensus target price of $46.20.Read Our Latest Research Report on CNMD<h2>CONMED Stock Up 0.2%</h2>NYSE CNMD opened at $36.72 on Friday. The company has a current ratio of 2.14, a quick ratio of 1.01 and a debt-to-equity ratio of 0.81. The stock's 50 day moving average is $38.63 and its two-hundred day moving average is $41.13. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of 20.75, a PEG ratio of 1.61 and a beta of 0.94. CONMED has a 1-year low of $33.21 and a 1-year high of $61.08. CONMED (NYSE:CNMD - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The company reported $0.89 earnings per share for the quarter, beating analysts' consensus estimates of $0.82 by $0.07. CONMED had a return on equity of 13.85% and a net margin of 4.00%.The company had revenue of $317.05 million for the quarter, compared to the consensus estimate of $310.64 million. During the same period in the previous year, the business earned $0.95 earnings per share. The company's quarterly revenue was down 1.3% on a year-over-year basis. Equities analysts forecast that CONMED will post 4.37 earnings per share for the current fiscal year. <h2>Institutional Inflows and Outflows</h2>Institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new position in CONMED in the 4th quarter worth approximately $26,000. Kelleher Financial Advisors bought a new position in CONMED in the 3rd quarter worth approximately $28,000. Aster Capital Management DIFC Ltd raised its position in CONMED by 409.2% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 723 shares of the company's stock worth $29,000 after purchasing an additional 581 shares during the last quarter. Quarry LP raised its position in CONMED by 244.8% in the 3rd quarter. Quarry LP now owns 869 shares of the company's stock worth $41,000 after purchasing an additional 617 shares during the last quarter. Finally, Huntington National Bank raised its position in CONMED by 111.8% in the 3rd quarter. Huntington National Bank now owns 883 shares of the company's stock worth $42,000 after purchasing an additional 466 shares during the last quarter. <h2>CONMED News Roundup</h2>Here are the key news stories impacting CONMED this week:<ul> <li>Positive Sentiment: Q1 results beat expectations — CONMED reported $0.89 EPS vs. a $0.82 consensus and revenue of $317.1M vs. $310.6M expected; earnings/revenue beats support near-term sentiment and helped calm concerns about recent year-over-year softness. Q1 Earnings Release</li> <li>Positive Sentiment: Management raised the organic growth outlook and outlined strategic actions — CONMED now targets 2026 organic growth of roughly 5.0%–6.5%, is exiting the GI business to sharpen focus on higher-growth surgical platforms, and is pursuing debt refinancing to improve the capital structure; those moves aim to lift margins and growth quality over the medium term. Growth Outlook / Strategy</li> <li>Positive Sentiment: Analyst takeaways and call materials provide color on execution — sell-side coverage and the earnings call/transcript highlight the company’s plan to refocus and where management expects near-term pressure vs. longer-term upside. Earnings Call Highlights</li> <li>Neutral Sentiment: Coverage pieces and deep dives summarize the strategy shift — several outlets (MSN, Zacks, Seeking Alpha) detail the GI exit and segment focus; useful for modeling but not an immediate catalyst by itself. Deep Dive: GI Exit</li> <li>Negative Sentiment: Wells Fargo cut its price target to $39 (from $42) and set an &#34;equal weight&#34; rating — the new PT implies only modest upside (~6% at current levels), reducing the near-term analyst-driven upside. Wells Fargo PT Cut</li> <li>Negative Sentiment: JPMorgan cut its price target to $40 (from $43) with a &#34;neutral&#34; rating — another downward PT move that keeps analyst expectations conservative despite the earnings beat. JPMorgan PT Cut</li> </ul><h2>About CONMED</h2> (Get Free Report)CONMED Corporation NYSE: CNMD is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company's product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology. CONMED operates two principal segments: Orthopedics, and Visualization &amp; Energy.<h2>See Also</h2><ul><li>Five stocks we like better than CONMED</li></ul><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNOTUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNOTUQ"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in CONMED Right Now?</h2>Before you consider CONMED, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CONMED wasn't on the list.While CONMED currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

CNMD

Wall Street Zen downgraded CONMED (NYSE:CNMD) from a "strong-buy" to a "buy" rating. Other firms have also adjusted their ratings, with Zacks upgrading to "hold" and Wells Fargo lowering the target price from $42 to $39. Currently, CONMED has a consensus rating of "Reduce" and a target price of $46.20. The stock opened at $36.72, with a market cap of $1.11 billion. Recent earnings showed $0.89 EPS, beating estimates, but revenue declined 1.3% year-over-year. Analysts forecast 4.37 EPS for the fiscal year.

CONMED (NYSE:CNMD) Stock Rating Lowered by Wall Street Zen